IPP Bureau

Lupin receives USFDA approval for travoprost ophthalmic solution
Lupin receives USFDA approval for travoprost ophthalmic solution

By IPP Bureau - May 07, 2024

Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Suven Life Sciences posts Q4 FY24 consolidated loss at Rs. 26.54 Cr
Suven Life Sciences posts Q4 FY24 consolidated loss at Rs. 26.54 Cr

By IPP Bureau - May 07, 2024

The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024

Dr. Reddy's Laboratories launches Doxycycline Capsules, 40 mg in US
Dr. Reddy's Laboratories launches Doxycycline Capsules, 40 mg in US

By IPP Bureau - May 06, 2024

ORACEA is a trademark of Galderma Holdings, S.A.

Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals
Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals

By IPP Bureau - May 06, 2024

Eugia Pharma Specialities receives 7 observations from USFDA for Unit II

Amrutanjan Health Care to set up Rs. 132 crore plant for sanitary napkins
Amrutanjan Health Care to set up Rs. 132 crore plant for sanitary napkins

By IPP Bureau - May 06, 2024

The project funding will be done through a mix of internal accruals and debts.

Zydus Wellness launches pilot for ready-to-drink beverage Glucon-D Activors
Zydus Wellness launches pilot for ready-to-drink beverage Glucon-D Activors

By IPP Bureau - May 06, 2024

The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness

Tatva Chintan Pharma Chem posts Q4 FY24 PAT at Rs. 9.61 Cr
Tatva Chintan Pharma Chem posts Q4 FY24 PAT at Rs. 9.61 Cr

By IPP Bureau - May 06, 2024

The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024

Astec LifeSciences posts Q4FY24 consolidated loss at Rs. 97.39 lakhs
Astec LifeSciences posts Q4FY24 consolidated loss at Rs. 97.39 lakhs

By IPP Bureau - May 04, 2024

The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024

Dabur India posts Q4 FY24 consolidated PAT at Rs. 349.53 Cr
Dabur India posts Q4 FY24 consolidated PAT at Rs. 349.53 Cr

By IPP Bureau - May 04, 2024

The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024

Wipro to implement Independent Health’s Medicare prescription payment plan platform
Wipro to implement Independent Health’s Medicare prescription payment plan platform

By IPP Bureau - May 04, 2024

Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions

Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr
Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr

By IPP Bureau - May 04, 2024

The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024

Bayer secures full ownership in Bayer Zydus Pharma by acquiring remaining 25% stake
Bayer secures full ownership in Bayer Zydus Pharma by acquiring remaining 25% stake

By IPP Bureau - May 03, 2024

The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market

RPG Life Sciences posts Q4 FY24 PAT at Rs. 13.24 Cr
RPG Life Sciences posts Q4 FY24 PAT at Rs. 13.24 Cr

By IPP Bureau - May 03, 2024

The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024

Novartis to acquire Mariana Oncology for upfront US$ 1 billion
Novartis to acquire Mariana Oncology for upfront US$ 1 billion

By IPP Bureau - May 03, 2024

Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications

Moderna posts Q1 2024 revenues at US$167 million
Moderna posts Q1 2024 revenues at US$167 million

By IPP Bureau - May 03, 2024

GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)

Latest Stories

Interviews

Packaging